FDA Authorizes First Continuous Glucose

What Did the FDA Authorize for Diabetes Monitoring?

The Libre Duo 10 Day Continuous Dual Glucose Ketone Monitoring System is authorized for people aged 2 years and older living with diabetes. Conventional continuous glucose monitors show glucose levels and trends, while ketones generally require a separate blood or urine test. Combining both measurements in a wearable system may give patients and caregivers a more complete view of changing metabolic risk.

The authorization represents an important advance in diabetes monitoring rather than a new treatment. The system does not administer insulin, correct high glucose or treat diabetic ketoacidosis. Its clinical value will depend on accurate use, understanding trend information and following the device labeling when readings or symptoms require confirmation or medical attention.

Why Is Continuous Ketone Monitoring Important?

Ketones accumulate when the body cannot use enough glucose for energy and increasingly breaks down fat. In people with diabetes, especially those with insufficient insulin, excessive ketone production can progress to diabetic ketoacidosis, or DKA. This is a medical emergency that can involve dehydration, vomiting, abdominal pain, deep or rapid breathing, confusion and loss of consciousness.

Ketone testing is particularly relevant during illness, persistent hyperglycemia, interrupted insulin delivery or symptoms suggestive of DKA. A wearable monitor could reduce the practical barrier of stopping to perform a separate ketone test and may reveal trends between individual checks. However, continuous data should complement established sick-day plans and professional advice rather than create reassurance when serious symptoms are present.

How Could the Dual Monitor Change Diabetes Care?

Viewing glucose and ketone information together may help users interpret why a high glucose reading is more concerning in some situations than in others. It may also be useful for parents and caregivers of children with diabetes, provided they receive training on alerts, trend arrows, confirmatory testing and thresholds for contacting the diabetes team.

Important questions remain about performance during rapid metabolic changes, real-world alert burden, affordability and insurance coverage. Clinicians will also need to integrate the additional data into practical care plans without encouraging unnecessary treatment changes. Anyone with vomiting, breathing difficulty, confusion or other possible signs of DKA should seek urgent medical assessment regardless of a wearable reading.